270 related articles for article (PubMed ID: 18289733)
41. Inhibition of sphingomyelin synthase 1 ameliorates alzheimer-like pathology in APP/PS1 transgenic mice through promoting lysosomal degradation of BACE1.
Lu MH; Ji WL; Xu DE; Yao PP; Zhao XY; Wang ZT; Fang LP; Huang R; Lan LJ; Chen JB; Wang TH; Cheng LH; Xu RX; Liu CF; Puglielli L; Ma QH
Exp Neurol; 2019 Jan; 311():67-79. PubMed ID: 30243987
[TBL] [Abstract][Full Text] [Related]
42. BACE1 SUMOylation increases its stability and escalates the protease activity in Alzheimer's disease.
Bao J; Qin M; Mahaman YAR; Zhang B; Huang F; Zeng K; Xia Y; Ke D; Wang Q; Liu R; Wang JZ; Ye K; Wang X
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):3954-3959. PubMed ID: 29581300
[TBL] [Abstract][Full Text] [Related]
43. Translational control of BACE1 may go awry in Alzheimer's disease.
Wong PC
Neuron; 2008 Dec; 60(6):941-3. PubMed ID: 19109900
[TBL] [Abstract][Full Text] [Related]
44. Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice.
Li S; Hou H; Mori T; Sawmiller D; Smith A; Tian J; Wang Y; Giunta B; Sanberg PR; Zhang S; Tan J
Sci Rep; 2015 Jun; 5():11322. PubMed ID: 26091071
[TBL] [Abstract][Full Text] [Related]
45. The BACE1-Specific DNA Aptamer A1 Rescues Amyloid-β Pathology and Behavioral Deficits in a Mouse Model of Alzheimer's Disease.
Liang ZM; Peng YH; Chen Y; Long LL; Luo HJ; Chen YJ; Liang YL; Tian YH; Li SJ; Shi YS; Zhang XM
Nucleic Acid Ther; 2019 Dec; 29(6):359-366. PubMed ID: 31513457
[TBL] [Abstract][Full Text] [Related]
46. Lessons from a BACE1 inhibitor trial: off-site but not off base.
Lahiri DK; Maloney B; Long JM; Greig NH
Alzheimers Dement; 2014 Oct; 10(5 Suppl):S411-9. PubMed ID: 24530026
[TBL] [Abstract][Full Text] [Related]
47. Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis.
O'Connor T; Sadleir KR; Maus E; Velliquette RA; Zhao J; Cole SL; Eimer WA; Hitt B; Bembinster LA; Lammich S; Lichtenthaler SF; Hébert SS; De Strooper B; Haass C; Bennett DA; Vassar R
Neuron; 2008 Dec; 60(6):988-1009. PubMed ID: 19109907
[TBL] [Abstract][Full Text] [Related]
48. Knock-in of human BACE1 cleaves murine APP and reiterates Alzheimer-like phenotypes.
Plucińska K; Crouch B; Koss D; Robinson L; Siebrecht M; Riedel G; Platt B
J Neurosci; 2014 Aug; 34(32):10710-28. PubMed ID: 25100603
[TBL] [Abstract][Full Text] [Related]
49. New BACE1 Chimeric Peptide Inhibitors Selectively Prevent AβPP-β Cleavage Decreasing Amyloid-β Production and Accumulation in Alzheimer's Disease Models.
Resende R; Ferreira-Marques M; Moreira P; Coimbra JRM; Baptista SJ; Isidoro C; Salvador JAR; Dinis TCP; Pereira CF; Santos AE
J Alzheimers Dis; 2020; 76(4):1317-1337. PubMed ID: 32597812
[TBL] [Abstract][Full Text] [Related]
50. Research status of the regulation of miRNA on BACE1.
Deng Y; Ding Y; Hou D
Int J Neurosci; 2014 Jul; 124(7):474-7. PubMed ID: 24147552
[TBL] [Abstract][Full Text] [Related]
51. miR-186 is decreased in aged brain and suppresses BACE1 expression.
Kim J; Yoon H; Chung DE; Brown JL; Belmonte KC; Kim J
J Neurochem; 2016 May; 137(3):436-45. PubMed ID: 26710318
[TBL] [Abstract][Full Text] [Related]
52. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression.
Hébert SS; Horré K; Nicolaï L; Papadopoulou AS; Mandemakers W; Silahtaroglu AN; Kauppinen S; Delacourte A; De Strooper B
Proc Natl Acad Sci U S A; 2008 Apr; 105(17):6415-20. PubMed ID: 18434550
[TBL] [Abstract][Full Text] [Related]
53. β-Secretase-1 elevation in aged monkey and Alzheimer's disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and β-amyloid accumulation.
Cai Y; Xiong K; Zhang XM; Cai H; Luo XG; Feng JC; Clough RW; Struble RG; Patrylo PR; Chu Y; Kordower JH; Yan XX
Eur J Neurosci; 2010 Oct; 32(7):1223-38. PubMed ID: 20726888
[TBL] [Abstract][Full Text] [Related]
54. Cdk5 protein inhibition and Aβ42 increase BACE1 protein level in primary neurons by a post-transcriptional mechanism: implications of CDK5 as a therapeutic target for Alzheimer disease.
Sadleir KR; Vassar R
J Biol Chem; 2012 Mar; 287(10):7224-35. PubMed ID: 22223639
[TBL] [Abstract][Full Text] [Related]
55. BACE1 Mediates HIV-Associated and Excitotoxic Neuronal Damage Through an APP-Dependent Mechanism.
Stern AL; Ghura S; Gannon PJ; Akay-Espinoza C; Phan JM; Yee AC; Vassar R; Gelman BB; Kolson DL; Jordan-Sciutto KL
J Neurosci; 2018 May; 38(18):4288-4300. PubMed ID: 29632166
[TBL] [Abstract][Full Text] [Related]
56. Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic.
Hook G; Yu J; Toneff T; Kindy M; Hook V
J Alzheimers Dis; 2014; 41(1):129-49. PubMed ID: 24595198
[TBL] [Abstract][Full Text] [Related]
57. 7,8-dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease.
Devi L; Ohno M
Neuropsychopharmacology; 2012 Jan; 37(2):434-44. PubMed ID: 21900882
[TBL] [Abstract][Full Text] [Related]
58. BACE1 elevation engendered by GGA3 deletion increases β-amyloid pathology in association with APP elevation and decreased CHL1 processing in 5XFAD mice.
Kim W; Ma L; Lomoio S; Willen R; Lombardo S; Dong J; Haydon PG; Tesco G
Mol Neurodegener; 2018 Feb; 13(1):6. PubMed ID: 29391027
[TBL] [Abstract][Full Text] [Related]
59. Beta-site amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of endogenous amyloid beta in wild-type and transgenic mice in vivo.
Hirata-Fukae C; Sidahmed EH; Gooskens TP; Aisen PS; Dewachter I; Devijver H; Van Leuven F; Matsuoka Y
Neurosci Lett; 2008 Apr; 435(3):186-9. PubMed ID: 18343582
[TBL] [Abstract][Full Text] [Related]
60. BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer's Disease Pathology.
Koelsch G
Molecules; 2017 Oct; 22(10):. PubMed ID: 29027981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
